Discover 466 paid clinical trials in Little Rock, Arkansas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 466
FeaturedActive & Responsive
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
for
Muscular Atrophy, Spinal
Location: Little Rock AR, Dallas TX, Atlanta GA, Grand Rapids MI,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 0 - 2
Code: NCT05861999
Recruiting
Featured
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
for
Muscular Atrophy, Spinal
Location: Little Rock AR, Dallas TX, Fort Worth TX, Atlanta GA,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 0 - 2
Code: NCT05861986
Recruiting
Featured
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
for
Acute Myeloid Leukemia
Location: Little Rock AR, Memphis TN, Jackson MS, St Louis MO,
Sponsor: PedAL BCU, LLC
Sex: All
Age: 0 - 21
Code: NCT05183035
Phase3, Recruiting
Active & Responsive
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
for
Juvenile Psoriatic Arthritis
Location: Little Rock AR, Austin TX, Indianapolis IN,
Sponsor: AbbVie
Sex: All
Age: 5 - 17
Code: NCT06100744
Phase3, Recruiting
Active & Responsive
PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia
Location: Little Rock AR, Chapel Hill NC, Greenville NC,
Sponsor: Duke University
Sex: All
Age: 0
Code: NCT07101640
Phase1, Phase2, Recruiting
Active & Responsive
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
for
Spinal Muscular Atrophy (SMA)
Location: Little Rock AR, Flower Mound TX, Iowa City IA,